Docket No.: WOLFRUM Serial No.: 09/669,236

REMARKS

The last Office Action of August 21, 2003 has been carefully considered.

Reconsideration of the instant application in view of the foregoing amendments

and the following remarks is respectfully requested.

Claims 21-23 have been corrected as claims 18-20, so that Claims 17-20

are pending in the application. Claim 19 has been amended. No claims have been

canceled. Claim 21 has been added. A total of 4 claims is now on file. No claim

surcharge is due.

Claims 17 to 20 stand rejected under 35 U.S.C. §103(a) as being

unpatentable over U.S. Pat. No. 6,70,316 (hereinafter "Sena").

The Examiner has objected to the Applicant's numbering of claims 21-23

whereby according to the Examiner claims 18-20 were never cancelled. Applicant

therefore accepts the current numbering as being from 18-20 with a new claim 21

added.

With respect to the priority of the application, applicant states that priority is

claimed under 35 U.S.C. § 119. Priority documentation was supposed to have

been forwarded to the Office through the International Bureau. However, if

documentation thereof is still required, the Examiner is requested to advise the

undersigned.

Docket No.: WOLFRUM Serial No.: 09/669,236

REJECTION OF CLAIM 19 UNDER 35 U.S.C. §112 SECOND PARAGRAPH

The Examiner pointed out that the term "in particular' renders the claim

indefinite. In response thereto, applicant has presented new claim 21 in which the

preferred feature is recited. The rejection is now moot.

Withdrawal of the rejection of claim 19 under 35 U.S.C. §112 second

paragraph is respectfully requested.

REJECTION OF CLAIMS 17-20 UNDER 35 U.S.C. §103(a) AS BEING

UNPATENTABLE OVER SENA.

The rejection is respectfully traversed.

Applicant has previously amended claim 17 to recite that the intensity

measurement of the light scattering in the probe is exclusively from the DNA and

RNA thereby distinguishing from the prior art cited in prior Official Actions.

Subsequently applicant filed an RCE. The Examiner has now cited a further

reference to Sena against the application. Sena is directed to Diagnostic

Applications of Double D-Loop Formation.

The Examiner points to col. 39, lines 20-40 as teaching the claimed

invention. However, Sena teaches in col. 39, lines 20-40 synthesis of a DNA probe

using PCR and in a further step the synthesized DNA probe is centrifuged through

a column and recovered by ethanol precipitation. In a further step, the DNA probe

Docket No.: WOLFRUM Serial No.: 09/669,236

is then resuspended in a buffer. Subsequent measurements are directed to the concentration by measuring OD at 260nm, i.e. by a light absorption measurement. However, these steps are familiar to those skilled in the art.

The invention as presently claimed differs from the Sena in that it is directed to the detection of the amplification of DNA and/or RNA sequences. The steps taken are as follows:

a) providing a sample containing at least a DNA or RNA sequence amplification reaction mixture; b) inputting light into the sample; c) detecting a scattered light intensity produced by the sample with a detector; d) treating the sample under conditions suitable fro amplifying at least said DNA or RNA sequences in order to produce amplified DNA and/or RNA sequences; d) determining the amplification of DNA or RNA sequences in the sample from an increase of the scattered light intensity, which light is scattered exclusively by the DNA or RNA.

In Sena in contrast, there is no teaching of the features as recited in step c) and e) of the present invention. Sena only determines <u>light absorption</u>, hence only the simple measuring of OD. In contrast thereto, in the claimed invention the <u>intensity of the scattered light</u> is determined. Through the feature of step e) the outcome of the PCR amplification reaction can be monitored online. With the teaching in Sena it is only possible to directly measure a sample without more steps to be taken that is after some time. With the method of the present invention the intensity of light scattered by DNA or RNA is observed. There is no measurement of this type in Sena. The method of the present invention has the advantage over the prior art that the manner of determining the outcome of the a

Docket No.: WOLFRUM Serial No.: 09/669,236

PCR amplification is very simple and significantly, the need for steps such as centrifugation, precipitations and resuspension as taught by Sena are thus superfluous.

While absorption refers to a process whereby energy of light radiation is transferred to a medium through which it is passing, the measurement of the intensity of scattered light refers to a process whereby energy is removed from the beam of light radiation and reemitted without appreciable change in wavelength.

There is nothing in Sena that points to the need or a motivation to use any other method of detecting the amplification than the one mentioned. Sena is not directed to method of determining an amplification reaction, absorption measurements are mentioned in passing as part of a conventional manner in which to determine the OD of the reconstituted reaction products. Therefore, Sean neither point into a direction of a different method not gives any motivation to do so.

Accordingly, the present invention claims a very different method to measuring the results of an amplification reaction, which patentably distinguishes from the cited reference.

It is noted that each named inventor of the subject matter of the instant application contributed at least to one of the claims, presently on file and that the inventor and date of invention of each claim was commonly owned.

Withdrawal of the rejection of claims 17-20 under 35 U.S.C. §103(a) and allowance thereof are thus respectfully requested.

GENERAL COMMENTS

In this connection, it is noted that the Examiner has acknowledged

applicants' claim for priority but questioned the basis for the priority. Applicant

states that its priority is claimed under 35 U.S.C. 120. If a copy of the priority

document is not on file, applicant will provide the documentation. Since the

present application was formerly prosecuted by another agent, applicant is not

fully apprised of what documentation was filed. Applicant believes that the issues

directed to the claim of priority has been addressed and obviated, however if there

are any remaining issues, the applicant respectfully requests to be apprised of any

omission.

CONCLUSION

Applicant believes that when the Examiner reconsiders the claims in the

light of the above comments, he will agree that the invention is in no way properly

met or anticipated or even suggested by any of the references however they are

considered.

None of the references discloses a method of measuring amplified DNA

and/or RNA sequences directly by determining the intensity of light scattering

directly from the sample probe.

Docket No.: WOLFRUM Serial No.: 09/669,236

In view of the above presented remarks and amendments, it is respectfully

submitted that all claims on file should be considered patentably differentiated over

the art and should be allowed.

Reconsideration and allowance of the present application are respectfully

requested.

Should the Examiner consider necessary or desirable any formal changes

anywhere in the specification, claims and/or drawing, then it is respectfully

requested that such changes be made by Examiner's Amendment, if the Examiner

feels this would facilitate passage of the case to issuance. If the Examiner feels

that it might be helpful in advancing this case by calling the undersigned, applicant

would greatly appreciate such a telephone interview.

The Commissioner is hereby authorized to charge fees, which may be

required, or credit any overpayment to Deposit Account No. 06-0502.

Respectfully submitted,

Rv.

Ursula B. Day

Attorney For Applicant

Reg. No: 47,296

Date: December 11, 2003

350 Fifth Avenue

Suite 4714

New York, N.Y. 10118

Phone (212) 244-5500

Fax (212) 244-2233

UBD:be